Alvotech SDB
Alvotech SDB is the Swedish depositary receipt of Alvotech, an Iceland-based biopharmaceutical company focused on developing and manufacturing biosimilar medicines. The business combines biosimilar product development, commercial supply, and out-licensing arrangements with partners that market the products in defined territories worldwide.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2024–2025
Liiketoiminta
Osuus liikevaihdostaDevelopment of biosimilar candidates designed to match reference biologics.
Sales of approved biosimilar products supplied to commercial partners or market channels.
Territory-based licensing arrangements with upfront, milestone, and commercialization rights.
Partnered development work tied to licensed biosimilar compounds.
Asiakkaat
Alvotech sells primarily to commercial partners and licensees, not directly to end patients. These partners acquire territorial rights, development support, and supply agreements so they can register, market, and distribute biosimilar products in their own markets. The business also serves partners that buy finished product supply after approval and commercialization.
Buy territorial rights, development support, and supply agreements so they can commercialize biosimilars in their markets.
Purchase approved biosimilar product for distribution and sale in assigned territories.
Fund and use partnered development programs tied to biosimilar candidates and milestones.
Strategia
Alvotech’s strategy centers on advancing a biosimilar pipeline, securing commercialization partners, and monetizing products through territory-specific out-licensing and supply agreements. The company also focuses on manufacturing and development capabilities that support multiple partnered launches across regions, which is essential in a business where scale and regulatory execution drive access to markets.
Approved products and filed candidates are the basis for future partner launches and supply revenue.
Third-party partners provide market access in territories where Alvotech does not sell directly.
Biosimilar commercialization depends on consistent production quality and supply to partners.
Maantiede
Alvotech earns revenue across Europe, the USA, and Rest of World markets, with Europe the largest geography in the latest annual disclosure. The company’s operational footprint is international, with manufacturing and development rooted in Iceland and a commercialization model that relies on partners in multiple territories. Geography matters because out-license rights are tied to specific countries or regions, which shapes where product revenue and milestone income are recognized.
Riskit
Alvotech faces the typical biotech risks of uncertain R&D outcomes, regulatory delays, and execution risk in manufacturing complex biologics. Its business model also depends heavily on third-party commercial partners and long-term financing, so any disruption in partner demand, launch timing, or funding access can materially affect operations.
- Reliance on commercial partnersVaikutus: KorkeaTodennäköisyys: Korkea
The company does not independently commercialize most products and depends on partners for market access.
Kohdistuu: Out-license contracts
- Customer concentrationVaikutus: KorkeaTodennäköisyys: Korkea
A few customers account for a large share of annual revenue.
Kohdistuu: Top commercial partners
- R&D and regulatory failureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Biosimilar candidates must prove comparability, safety, and efficacy before approval.
Kohdistuu: Pipeline programs
- Foreign exchange volatilityVaikutus: KeskitasoTodennäköisyys: Korkea
Revenue, assets, liabilities, and financing span EUR, GBP, ISK, CHF, and USD.
Kohdistuu: Multi-currency operations
Kirjanpito
Harkinnanvaraiset erätProduct revenue is recognized when control passes on shipment, making timing sensitive to logistics and cut-off.
Vaikutus: Quarterly revenue comparability
Rebates, returns, chargebacks, and other adjustments reduce recognized net selling price.
Vaikutus: Net revenue and gross margin presentation
License, development services, and supply can be separate performance obligations.
Vaikutus: Timing and allocation of contract revenue
Significant balances are denominated in currencies other than the functional currency.
Vaikutus: Equity, finance income/costs, and volatility
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Alvotech
ALVO · Biological Products, (No Diagnostic Substances)
Alvotech is a U.S.-listed biotechnology company focused on developing and manufacturing biosimilar medicines.
Swedish Orphan Biovitrum
SOBI · Health Care
Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company dedicated to transforming the lives of individuals with rare and debilitating diseases.
BioNTech SE
BNTX · Biological Products, (No Diagnostic Substances)
BioNTech SE is a biotechnology company focused on discovering and developing immunotherapies and other medicines, with a major commercial base in COVID-19 vaccines and a growing oncology pipeline.
AbCellera Biologics Inc.
ABCL · Pharmaceutical Preparations
Assembly Biosciences, Inc
ASMB · Pharmaceutical Preparations
Arbutus Biopharma Corp
ABUS · Pharmaceutical Preparations
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious disease, with its current development efforts centered on chronic hepatitis B.
Päivitetty: 28.9.2026